Alexandre Moreau, a highly accomplished pharmaceutical executive, is known for his exceptional leadership, global awareness, and deep expertise in the pharmaceuticals and biotech industry. With over 25 years of experience in leading top-tier pharmaceutical and biotech companies, Alexandre has a successful track record of bringing innovative strategies to life and driving high performance across multicultural teams.

Alexandre's accomplishments include the creation of innovative launch campaigns, building high-performing teams, driving complex strategic projects, and bringing life-changing therapies to patients worldwide. He is a hands-on leader who is highly regarded for his integrity, motivation, and passion for making a meaningful difference for patients and physicians.

Alexandre is an alumnus of several leading universities, including Harvard Business School, INSEAD, and Sorbonne Graduate Business School. He holds a Doctor in Pharmacy from the University of Biological & Pharmaceutical Sciences-Paris, France.

Currently, Alexandre serves as Vice President of the Global Leadership Team at UCB GLOBAL BONE PATIENT VALUE UNIT & UCB GLOBAL EPILEPSY PORTFOLIO - HEADQUARTERS. He has also served as the Advisory Board Member at DEFYMED SAS, co-founder and shareholder at AXXELIS AG, Chief Executive Officer at KYMO THERAPEUTICS LIMITED, Chief Executive Officer at MAVALON THERAPEUTICS LIMITED, Global Product Strategy -Vice President, Life Cycle Leader at ROCHE GENENTECH, and Global Marketing -Vice President; Head of Global Franchise at SANOFI.